Dr. Keyvan Karkouti and I discussed the FARES-II trial. PCC is superior to FP for hemostasis in managing excessive bleeding among cardiac surgery ptS with coagulopathy. March 29, 2025 Disclosures: TBD
Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide improves functional outcomes in DM pts with symptomatic PAD, addressing a critical unmet need. March 29, 2025 Disclosures: TBD
THIS WEEK IN OBESITY: Gibson and Dr. Perreault discuss the possibility or lack thereof that we can prevent and/or reverse diabetes and obesity. March 6, 2025
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 Disclosures: TBD
von Willebrand factor molecules cross link and form a net around a blood clot holding it together. Drs. Shahid Nimjee and Gibson discuss a new vWf inhibitor that breaks apart this net & opening closed arteries but leaving a patch of fibrin strands across the site of plaque rupture which would have been dissolved by fibrinolytics potentially causing bleeding. December 4, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) November 18, 2024 Disclosures: TBD
Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial November 18, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN) November 18, 2024 Disclosures: TBD
Dr. Steven E Nissen and Dr. C. Michael Gibson Discuss: ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks. November 18, 2024 Disclosures: TBD
Daniel P Judge and Dr. C. Michael Gibson Discuss: Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study November 18, 2024 Disclosure: Sponsored by BridgeBio
